Human platelet thromboxane A2/prostaglandin H2 (TXA2/ PGH2) receptors are linked to phosphoinositide-specific phospholipase C (PI-PLC) via a G protein tentatively identified as a member of the Gq class. In contrast, platelet thrombin receptors appear to activate PI-PLC via other unidentified G pro-, teins. Platelets from most dogs are TXA2 insensitive (TXA2-); i.e., they do not aggregate irreversibly or secrete although they bind TXA2, but they respond normally to thrombin. In contrast, a minority of dogs have TXA2-sensitive (TXA2+) platelets that are responsive to TXA2. To determine the mechanism responsible for TXA2-platelets, we evaluated receptor activation of PI-PLC. Equilibrium binding of TXA2/PGH2 receptor agonists, 1251IBOP and 13H1U46619, and antagonist, 13H1SQ29,548, revealed comparable high-affinity binding to TXA2-, TXA2+, and human platelets. U46619-induced PI-PLC activation was impaired in TXA2-platelets as evidenced by reduced (a) phosphorylation of the 47-kD substrate of protein kinase C, (b) phosphatidic acid (PA) formation, (c) rise in cytosolic calcium concentration, and (d) inositol 1,4,5 trisphosphate (IP3) formation, while thrombin-induced PI-PLC activation was not impaired. GTPase activity stimulated by U46619, but not by thrombin, was markedly reduced in TXA2-platelets. Antisera to Gq class a subunits abolished U46619-induced GTPase activity in TXA2-, TXA2+, and human platelets. Direct G protein stimulation by GTPyS yielded significantly less PA and IP3 in TXA2-platelets. Immunotransfer blotting revealed comparable quantities of Gq class a-subunits in all three platelet types. Thus, TXA2-dog platelets have impaired PI-PLC activation in response to TXA2/PGH2 receptor agonists secondary to G protein dysfunction, presumably involving a
Introduction
Most dogs, mongrel or pure bred, have platelets that form TXA2, but fail to aggregate irreversibly or to secrete granular contents in response to the TXA2 formed (15) (16) (17) (18) (19) (20) . These TXA2-insensitive (TXA2-) platelets also fail to aggregate irreversibly or to secrete in response to TXA2 mimics such as (1 5S)-hydroxy-I Ia,9a (epoxymethano) prosta-5Z, 13E, dienoic acid (U46619). However, some mongrel dogs, and a few pure-bred strains, have platelets that are TXA2 sensitive (TXA2+) in that they aggregate and secrete in response to the TXA2 formed (18) (19) (20) as do platelets from nearly all humans. Each individual dog's platelet response to TXA2 is consistent and genetically defined (21 ) . TXA2-platelets aggregate irreversibly and secrete if exposed to thrombin or to subthreshold concentrations of epinephrine in addition to TXA2, and they aggregate in response to TXA2 plus subaggregating concentrations ofADP (18) (19) (20) . Dogs with TXA2-platelets do not have a bleeding diathesis; however, they have significantly less platelet deposition on prosthetic vascular grafts and significantly higher rates of graft patency than dogs with TXA2+ platelets (22) . Although very rare, TXA2 refractory human platelets that resemble dog TXA2-platelets have been described (see reference 23 for review).
The biochemical basis for the failure of TXA2-platelets to respond to TXA2 has not previously been determined. Although decreased TXA2/PGH2 receptor number or affinity for agonist could explain the functional behavior ofTXA2-platelets, high-affinity TXA2/PGH2 receptors with pharmacological and radioligand binding characteristics similar to human platelets were found to be present on dog platelets (24, 25) . This observation suggested the possibility that TXA2-platelets had a variant form ofpostreceptor stimulus-response coupling compared to human and TXA2+ platelets. Therefore, we studied the consequences of agonist-induced activation of PI-PLC in TXA2-platelets and compared the results with similar studies ofTXA2+ and human platelets. Ultimately our studies centered on the presence and function of Gp. The results of these studies indicate that TXA2-platelets have a functionally impaired TXA2/PGH2 receptor-linked Gp.
Methods
Subjects. All dogs studied were part ofa colony maintained in an AAA-LAC-certified animal care facility at the Minneapolis VA Medical Center. The animals' health was monitored by frequent examinations conducted by the facility's Veterinary Medical Officer. All dogs were healthy at the time ofstudy. Most ofthe dogs studied were the offspring of animals bred for the purpose of defining the mode of inheritance of dog TXA2-and TXA2+ platelets (21 ) . Platelets were obtained from normal healthy human volunteers who had taken no medication within the previous week. This study protocol was approved by the Animal Studies and Human Studies Subcommittees of the Research Committee of the Minneapolis VA Medical Center.
Materials. Sodium arachidonate was obtained from Nu Chek Prep, Elysian, MN. Iloprost was obtained from Berlex Laboratories, Wayne, NJ. ADP, bovine thrombin, and guanosine 5 '-0-(3-thiotrisphosphate) (GTP-yS) were from Sigma Chemical Co., St. Louis, MO, and epinephrine from Parke-Davis, Morris Plains, NJ. U466 19 was a gift from The Upjohn Company, Kalamazoo, MI. [3H]U46619, 6 .3 Ci/mmol, was prepared by Amersham Corp., Arlington Heights, IL., by custom labeling of cold U46619 (26) . The TXA2/PGH2 receptor antagonist, [IS- [ la,2,(5Z), 3 Platelet preparation. Blood was obtained without anesthesia from dogs conditioned to the blood drawing procedure by external jugular venipuncture using a 19-gauge needle and a multiple syringe technique (21) . Blood (9 ml) was added to 3.8% sodium citrate (1 ml), and after thorough mixing, platelet-rich plasma was obtained by centrifugation at 180 g for 15 min at room temperature. Human blood was obtained from an antecubital venipuncture, and platelet-rich plasma obtained as described above. Buffer suspended platelets were obtained from platelet-rich plasma by centrifugation (1,000 g, 20 min, 15°C in the presence of 10 mM EDTA [26] ) followed immediately by resuspension in an appropriate buffer. In aggregation, [4C] 5HT secretion and phosphorylation studies the buffer was Hepes Tyrode's buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.36 mM NaH2PO4, 1 mM MgCI2,5 mM Hepes, 5.5 mM glucose [pH 7.1]) or Lindon'sbuffer ( 19) .
Platelet aggregation and platelet ["C] 5HT secretion. Platelet aggregation and secretion were performed as previously described (18, 26) . Maximal responses to agonists were determined in each study. Since the amount of agonist required to achieve maximum responses varied among subjects, a concentration range is recorded.
Radioligand binding to TXA2/PGH2 receptors. Equilibrium binding of TXA2/PGH2 receptor agonists or antagonists to buffer-suspended platelets was performed as previously described (26) . Briefly, platelets were incubated with labeled and unlabeled ligand over a concentration range 10 (27) and CURFIT 4 (28) .
Protein phosphorylation. Phosphorylation of the 47-kD substrate (40K protein) of protein kinase C (PKC) was studied by SDS-PAGE (29) and scintillation counting as previously described (26) .
PKC. Washed platelets were resuspended to 1 X 1012 platelets/ml in breaking buffer (200 mM Tris HCI [pH 7.5] , 250 mM sucrose, 0.02% leupeptin, 1 mM PMSF, 10 mM jl-mercaptoethanol, 2 mM EDTA, 5 mM EGTA), sonicated in two 15-s bursts on ice, and spun at 100,000 g for 90 min. The PKC activity was then measured in the platelet extracts using a modification of the assay system of Go et al. IP3formation. Platelets resuspended in Hepes-Tyrode's buffer to a concentration of 6-8 X 108/ ml were warmed to 37°C and stimulated with U46619 or thrombin. Permeabilized platelets were prepared by incubation with saponin (16 ug/ml) as described above (see Phosphatidic acidformation). 20 s after the addition of U46619 or thrombin to intact platelets, or GTP-yS to permeabilized platelets, 200-Ml aliquots were removed, and perchloric acid was extracted, neutralized with 10 N KOH to pH 7.5-8.0, and assayed for IP3 by RIA.
GTPase activity. Platelet membranes were prepared as described by Baldassare et al. (7) . Platelets, 7-10 X 109 platelets/ml, suspended in TEA buffer with inhibitors (10 mM triethanolamine, 5 mM EDTA, 1.8 mM EGTA [pH 6.8], 0.5 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine, 100 ng/ml leupeptin, 10 mM dithiothreitol) were sonicated at 90 W on ice (5 s five times) and centrifuged 100,000 g for 30 min (Beckman TL-100 ultracentrifuge) and the resultant membranes were resuspended by sonication (5-10 Mtg/Ml). GTPase (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) Mg) were added to the reaction mixture (370C), and aliquots were taken immediately and at 4 min after the addition of membranes. The reaction was terminated with 0.5 ml 5% (wt/vol) Norit-A charcoal (20 mM sodium phosphate buffer, pH 7.4). The tubes were vortexed and centrifuged at 8,000 g for 2 min, and a 200-Mi aliquot ofsupernatant was removed for scintillation counting. Low-affinity (high Km) GTPase activity was assayed in the presence of 100 M GTP. High-affinity (low Km) GTPase activity was calculated from the cpm difference after subtraction oflow-affinity GTPase cpm and represented 2 71% of the 32P released for stimulated responses above 2 pmol. Blank values for this assay never exceeded 2% ofthe total radioactivity. In studies performed to evaluate the effect of antisera to a subunits of the Gq class, Gi, or GC on GTPase activity, membrane suspensions were mixed 9:1 (vol/vol) with antisera (generally 10 Ml) and kept on ice for 60 min before assay.
Antisera. Antisera to a subunits ofthe G. class (Table II) .
PKC activation. Maximal 40K protein phosphorylation in TXA2-platelets stimulated by U46619 or sodium arachidonate (TXA2 precursor) was only -50% of that observed in TXA2+ platelets, while thrombin-induced 40K protein phosphorylation was equal in TXA2-and TXA2+ platelets (Fig.  2) . The 40K protein phosphorylation pattern observed in TXA2+ platelets was very similar to that which we found previously in human platelets (26) . To ensure that the altered phosphorylation profile of TXA2-platelets was not the result of PKC deficiency, we evaluated the PKC activity in platelet extracts from both types of dogs. The Thrombin concentration 0.1-0.5 U/ml. * P < 0.005 compared to TXA2+ and human platelets.
( Fig. 3 A) and GTPyS (Fig. 3 B) was observed in permeabilized TXA2-platelets, and the results were compared to permeabilized TXA2+ and human platelets. At 0.5, 1, and 2 min after the addition of U466 19, TXA2-platelets formed less PA than either TXA2+ or human platelets (Fig. 3 A) . At 2 min, PA production stimulated by U446 19 in TXA2-platelets was decreased -40% compared with TXA2+ and human platelets (TXA2-vs. TXA2+, P = 0.042). PA formation by TXA2-platelets in response to GTPyS (Fig. 3 B) was also reduced (-50%) at 2 min compared with TXA2+ and human platelets (TXA2-vs. TXA2+, P = 0.002). To evaluate the source ofPA, TXA2-, TXA2+, and human platelets were 32P-labeled and extracted, and their respective phospholipid components were visualized by autoradiography after TLC. The amounts of endogenously labeled PIP2 and PI were similar for both types of dog and human platelets (data not shown).
To evaluate directly PI-PLC activity, crude membrane preparations from TXA2-, TXA2+, and human platelets were prepared and their basal activities evaluated using synthetic vesicles of phosphatidylethanolamine/ [3H]PIP2 (10:1 mole ratio). Both types of dog platelet membranes exhibited higher levels of basal PI-PLC activity (TXA2-, 63.9±26.9; TXA2+, 44.3±9.3 nmol/min per mg) than human platelet membranes (6.1±1.8 nmol/min per mg; n = 4). Underthese conditions we could not demonstrate stimulation ofPI-PLC activity by TXA2 mimics. IP3 formation. Since the studies above suggested impaired PI-PLC activation after TXA2/PGH2 receptor binding, we assessed in situ PI-PLC activation after agonist binding by assaying IP3 production. Basal IP3 production was similar in dog platelets and human platelets (Fig. 4) . Stimulation of intact platelets with U46619 resulted in less IP3 (pmol/2 x 0I platelets) produced by TXA2-platelets (0.50±0.66) than by TXA2+ platelets (3.9±2.0; P = 0.001) or human platelets (4.1±2.4; P = 0.003). Basal IP3 formation was not significantly different in permeabilized TXA2-and TXA2+ platelets (P = 0.078), but IP3 formation stimulated by direct G protein activation with GTPyS was reduced in TXA2-platelets (2.2±1.1) in comparison to TXA2+ platelets (6.8±3.0; P = 0.016) or human platelets (10.22±5.5; P = 0.015). However, intact platelet stimulation by thrombin resulted in IP3 formation by TXA2-platelets ( 11.3±2.6) that was not less than that formed by TXA2+ platelets (8.3±1.5) or human platelets (7.6±4. 1 ) (Fig. 4) . To define the G protein involved with the receptor, we evaluated the effects ofplatelet membrane incubation with antisera
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to Gal, Gal, and Gq class a-subunits on GTPase activity in were diluted over a 10-fold range and subjected to SDS-PAGE and subsequently immunoblotted. Our results, shown in Fig. 5 for solubilized whole cells, indicate apparently similar concentrations of Gaq in all three platelet types. In the three most concentrated whole-cell samples of dog platelets a distinct minor band of slightly greater molecular weight was observed (Fig. 5, lanes 7 and 8) . The identity of this band is uncertain, but it is possible that this represents a variant of Ga, present in dog platelets that is not present in human platelets. This second band was not seen in washed membrane preparations immunoblotted with the same antisera, nor was it recognized by antiserum X384. When whole cell preparations were diluted over a 10-fold range, electrophoresed, and immunoblotted with antiserum X384, the concentrations of Gaq/Ga1 also appeared similar (data not shown branes was not significantly affected by antisera specific for Ga,, (0.8±1.9; 4.1± 1.0) or Gai ( 1.4±0.5; 7.4±0.9). Comparable results were obtained with human platelet membranes (Table IV). U46619-stimulated GTPase activity (8.6±2.1) was abolished by both types of Gq class antisera ( 10.0±2.3 below basal and 4.4±1.6 below basal) but not significantly affected by antisera specific for Ga,, (5.7± 1.0) or Gai (6.5±1.3). Thrombin-stimulated GTPase activities of TXA2-, TXA2+, or human membranes showed no significant differences when incubated with antisera to GalZ, Gai, or Gaq/Gaii.
Immunotransfer blotting. Since antibodies to a subunits of the Gq class abolished the rise in GTPase activity stimulated by U466 19, we investigated the abundance of these a subunits in both types of dog, as well as human platelets. Immunotransfer blotting utilizing antiserum X384 or W082 demonstrated the presence of Gaq/Ga,, in comparable quantities in TXA2-, TXA2+, and human platelets (data not shown). In an attempt to further evaluate the absolute amounts of these G protein subunits, solubilized whole platelets and platelet membranes (45, 46) have also identified two platelet TXA2/PGH2 binding sites, one linked to shape change and the other to aggregation and secretion. In contrast, the antagonist radioligand, [3H]SQ29,548, bound to only a single site on human platelets, as previously described (47), and we observed a single site on TXA2-and TXA2+ platelets as well. Overall, we found no significant differences between TXA2-platelets and either TXA2+ or human platelets in regard to the characteristics of their high-affinity TXA2/PGH2 binding sites evaluated by equilibrium binding of agonist or antagonist radioligands.
Mais et al. (24) Thrombin responses in the presence of antisera to Gaq/ Gal,, GaZ, or Gai were not significantly different for any ofthe three platelet types. A nonsignificant reduction in mean thrombin-induced GTPase activity was observed in TXA2-platelets in the presence ofantisera to the carboxyl terminus of Gaq/Gall, but not in the presence of Gaq-specific antiserum.
Ifconfirmed by further study, this apparent reduction could be evidence in support of the suggestion (5) that thrombin receptors are linked to PI-PLC via G proteins of the Gq class, and that they activate one or more Gq class proteins other than Gaq.
Additional data that strongly suggest that TXA2-platelets have a dysfunctional GP linked to the TXA2/PGH2 receptor derived from our studies utilizing GTPyS. Both PA and IP3 formation were significantly reduced in permeabilized TXA2-platelets, compared to TXA2+ or human platelets, after direct G protein activation by GTPyS. Permeabilization alone has been shown to result in some IP3 production (49) . We confirmed this observation. However, we found no significant difference between the basal IP3 levels observed for saponin-permeabilized TXA2-and TXA2+ platelets, yet a threefold reduction in the response of TXA2-platelets to GTP~yS was observed.
In summary, dog TXA2-platelets demonstrate marked impairment of PI-PLC activation in response to agonist stimulation, despite the presence of adequate TXA2/PGH2 receptors, that is attributable to dysfunction of GP. We postulate that TXA2-platelets have a mutant form of GP, probably mutant Gaq or Ga11, that results in impaired signal transduction from the TXA2/PGH2 receptor to PI-PLC; however, at least two other alternatives are possible. A mutation in fry or in the heterotrimer binding domains ofthe TXA2/PGH2 receptor could result in functional defects consistent with some, but not all, aspects of our findings. fry subunits are essential for efficient coupling of a subunits to receptors (48) , and they appear to play important roles in modulating activation of effectors, including PI-PLC (40, (50) (51) (52) (53) . Similarly, a mutation in the second or third cytoplasmic loops of the receptor that interact with the heterotrimer (54), could reduce agonist-induced conformational change that results in a subunit release and activation. However, this would be unlikely to result in impaired activation of PI-PLC by GTPys.
Naturally occurring examples of G protein dysfunction are uncommon; therefore a close analogy to the postulated defect in the TXA2-platelet cannot be cited. However, the similarity of some of our findings in TXA2-platelets to those described in human platelets (23, 55, 56) suggests that the same Gp-related mechanism may be responsible for TXA2 insensitivity of both dog and human platelets. Another example that bears some resemblance to the dog TXA2-platelet is the impaired function of Gs in cardiac and skeletal muscle of cardiomyopathic Syrian hamsters (57, 58) . Dog TXA2-platelets and cardiomyopathic hamster myocytes are similar in that they both manifest impaired signal transduction from receptor to effector secondary to apparent G protein malfunction despite the presence of normal quantities of the relevant G protein a subunit. It has been suggested that the reduction in effector activation is likely the result of an alteration in the primary structure of the a subunit or in its post-translational modification that diminishes coupling from the receptor to the effector (57).
The postulated mutation in GP linked to the TXA2/PGH2 receptor ofTXA2-platelets remains to be defined. However, if the mutation exists in the a subunit, a G protein that may be analogous is the Gas mutation responsible for the H2 1 a phenotype in S49 mouse lymphoma cells. An amino acid substitution of alanine for glycine 226, that results in failure of the a subunit to undergo an appropriate conformational change necessary for a dissociation from /3y, is responsible for its functional impairment (59, 60) . This mutant G protein interacts normally with receptors, as evidenced by its ability to promote high-affinity binding of #-adrenergic receptor agonists, but it fails to activate its effector (adenylylcyclase) when stimulated via the receptor or directly by AIF-or GTP analogues. These characteristics are similar to those we have observed in TXA2-platelets. Further study of dog TXA2-platelets should yield new information regarding the regulation of GP.
